Research map: Potassium-Competitive Acid Blockers as a New Frontier in Acid-Related Disorders and the Role of South Korean Pharmacological Innovation

Back to the article

Papers in this map

  1. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report · Peter Malfertheiner · 2022 · 1513 citations · Cited by this paper
  2. Sarcosine-Based Pharmacokinetic Optimization and Fluorescent Dye Library Evaluation of Dual-Labeled PSMA Inhibitors for Fluorescence-Guided Surgery · 2026 · Related
  3. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions · Alessia Savoldi · 2018 · 1289 citations · Cited by this paper
  4. Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers · 2024 · Related
  5. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease · Philip O. Katz · 2021 · 1022 citations · Cited by this paper
  6. Antibody–Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors · 2026 · Related
  7. 25 Years of Proton Pump Inhibitors: A Comprehensive Review · Daniel S. Strand · 2016 · 676 citations · Cited by this paper
  8. Fucoidan Ameliorates Contrast-Induced Acute Kidney Injury in Mice by Modulating the TLR4/NF-κB and Nrf2/GPX4 Pathways · 2026 · Related
  9. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection · Patrick Omonua Erah · 1997 · 277 citations · Cited by this paper
  10. Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound–Indication Matching and Precision Neurotherapeutic Development · 2026 · Related
  11. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal · Vincenzo Savarino · 2016 · 270 citations · Cited by this paper
  12. Potential Adjunctive Effects of Quercetin–Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study · 2026 · Related
  13. Proton Pump Inhibitors: Review of Emerging Concerns · Avinash K. Nehra · 2018 · 260 citations · Cited by this paper
  14. Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK · 2026 · Related
  15. NERD: an umbrella term including heterogeneous subpopulations · Edoardo Vincenzo Savarino · 2013 · 223 citations · Cited by this paper
  16. Pharmacokinetics of the potassium-competitive acid blocker tegoprazan administered by the oral route in healthy Mexicans · 2026 · Related
  17. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases · Tadayuki Oshima · 2018 · 223 citations · Cited by this paper
  18. Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial · 2026 · Related
  19. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases · Nobuhiro Inatomi · 2016 · 161 citations · Cited by this paper
  20. Long-term use of potassium-competitive acid blockers and proton pump inhibitors and the risk of metachronous gastric cancer after H. pylori eradication: a multicenter cohort study · 2026 · Related
  21. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020 · Hye‐Kyung Jung · 2021 · 157 citations · Cited by this paper
  22. CYP2C19 polymorphism influencesHelicobacter pylorieradication · Chao‐Hung Kuo · 2014 · 124 citations · Cited by this paper
  23. Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders · Yousef Abdel‐Aziz · 2021 · 113 citations · Cited by this paper
  24. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility · Nobuyuki Takahashi · 2017 · 110 citations · Cited by this paper
  25. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel potassium‐competitive acid blocker, in healthy male subjects · Sungpil Han · 2019 · 109 citations · Cited by this paper
  26. Restoration of acid secretion following treatment with proton pump inhibitors · Jai Moo Shin · 2002 · 98 citations · Cited by this paper
  27. A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis · Daniel Martin Simadibrata · 2022 · 92 citations · Cited by this paper
  28. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects · Loren Laine · 2022 · 91 citations · Cited by this paper
  29. Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease? · Richard H. Hunt · 2015 · 89 citations · Cited by this paper
  30. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial · Yoon Jin Choi · 2022 · 89 citations · Cited by this paper
  31. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review · Amit C Patel · 2024 · 87 citations · Cited by this paper
  32. Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease · Seung Han Kim · 2021 · 74 citations · Cited by this paper
  33. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP 14012, a novel potassium‐competitive acid blocker, in healthy male subjects · Jung Sunwoo · 2018 · 73 citations · Cited by this paper
  34. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? · Prashanth Rawla · 2018 · 73 citations · Cited by this paper
  35. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments · Carmelo Scarpignato · 2024 · 73 citations · Cited by this paper
  36. Regional Difference of Antibiotic Resistance ofHelicobacter pyloriStrains in Korea · Jae Yeon Kim · 2011 · 65 citations · Cited by this paper
  37. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea · Jun‐Hyung Cho · 2022 · 61 citations · Cited by this paper
  38. Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives · Justyna Srebro · 2022 · 60 citations · Cited by this paper
  39. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects · Jung Sunwoo · 2020 · 47 citations · Cited by this paper

Source: OpenAlex (CC0)